Drugs Made In America Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering
Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) announced the successful closing of its initial public offering, raising $200 million in gross proceeds through the sale of 20,000,000 units at $10.00 per unit. The units, trading on the Nasdaq Global Market under 'DMAAU', include one ordinary share and one right to receive one-eighth of an ordinary share upon completing an initial business combination.
The company's ordinary shares and rights will eventually trade separately under the symbols 'DMAA' and 'DMAAR'. Clear Street served as the sole book-running manager, with Loeb & Loeb LLP as company counsel and Winston & Strawn LLP as Clear Street's counsel. The SEC declared the registration statement effective on January 7, 2025, with a post-effective amendment approved on January 27, 2025.
Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) ha annunciato la chiusura con successo della sua offerta pubblica iniziale, raccogliendo 200 milioni di dollari in proventi lordi attraverso la vendita di 20.000.000 di unità a 10,00 dollari ciascuna. Le unità, che vengono scambiate sul Nasdaq Global Market sotto 'DMAAU', includono un'azione ordinaria e un diritto di ricevere un ottavo di un'azione ordinaria al completamento di una combinazione aziendale iniziale.
Le azioni ordinarie della società e i diritti alla fine verranno scambiati separatamente sotto i simboli 'DMAA' e 'DMAAR'. Clear Street ha svolto il ruolo di unico manager book-running, con Loeb & Loeb LLP come consulente della società e Winston & Strawn LLP come consulente di Clear Street. La SEC ha dichiarato efficace la dichiarazione di registrazione il 7 gennaio 2025, con un'emendamento post-efficace approvato il 27 gennaio 2025.
Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) anunció el cierre exitoso de su oferta pública inicial, recaudando 200 millones de dólares en ingresos brutos a través de la venta de 20.000.000 de unidades a 10,00 dólares por unidad. Las unidades, que se cotizan en el Nasdaq Global Market bajo 'DMAAU', incluyen una acción ordinaria y un derecho a recibir un octavo de una acción ordinaria al completar una combinación empresarial inicial.
Las acciones ordinarias de la compañía y los derechos eventualmente se negociarán por separado bajo los símbolos 'DMAA' y 'DMAAR'. Clear Street actuó como el único gerente de libro, con Loeb & Loeb LLP como asesor de la empresa y Winston & Strawn LLP como asesor de Clear Street. La SEC declaró efectiva la declaración de registro el 7 de enero de 2025, con una enmienda posterior a la efectividad aprobada el 27 de enero de 2025.
Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU)는 기업공개(IPO)의 성공적인 마감을 발표하며, 2억 달러의 총 수익을 올렸습니다. 이는 20,000,000개의 단위를 각각 10.00 달러에 판매한 결과입니다. 'DMAAU'라는 이름으로 Nasdaq Global Market에서 거래되고 있는 이 단위는 하나의 보통주와 초기 사업 결합 완료 시 보통주의 1/8을 받을 수 있는 권리를 포함합니다.
회사의 보통주와 권리는 결국 'DMAA' 및 'DMAAR'이라는 기호로 별도로 거래될 것입니다. Clear Street는 유일한 북러닝 매니저로 활동하였고, Loeb & Loeb LLP는 회사의 자문을, Winston & Strawn LLP는 Clear Street의 자문을 맡았습니다. SEC는 2025년 1월 7일에 등록신청서를 효력 발생으로 선언하였고, 2025년 1월 27일에 효력 발생 후 수정안이 승인되었습니다.
Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) a annoncé la clôture réussie de son introduction en bourse, levant 200 millions de dollars de revenus bruts grâce à la vente de 20 000 000 d'unités au prix de 10,00 dollars par unité. Les unités, échangées sur le Nasdaq Global Market sous 'DMAAU', comprennent une action ordinaire et un droit de recevoir un huitième d'une action ordinaire lors de la réalisation d'une combinaison d'affaires initiale.
Les actions ordinaires de l'entreprise et les droits seront finalement échangés séparément sous les symboles 'DMAA' et 'DMAAR'. Clear Street a servi de gestionnaire exclusif, avec Loeb & Loeb LLP en tant que conseil de la société et Winston & Strawn LLP en tant que conseil de Clear Street. La SEC a déclaré la déclaration d'enregistrement effective le 7 janvier 2025, avec un amendement postérieur à l'efficacité approuvé le 27 janvier 2025.
Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) gab den erfolgreichen Abschluss seines Börsengangs bekannt und erzielte dabei 200 Millionen Dollar brutto durch den Verkauf von 20.000.000 Einheiten zu jeweils 10,00 Dollar. Die Einheiten, die unter 'DMAAU' an der Nasdaq Global Market gehandelt werden, bestehen aus einer Stammaktie und einem Recht, bei Abschluss einer ersten Unternehmenszusammenlegung ein Achtel einer Stammaktie zu erhalten.
Die Stammaktien des Unternehmens und die Rechte werden schließlich unter den Symbolen 'DMAA' und 'DMAAR' separat gehandelt. Clear Street fungierte als alleiniger Buchleiter, wobei Loeb & Loeb LLP als Unternehmensberater und Winston & Strawn LLP als Berater von Clear Street tätig waren. Die SEC erklärte die Registrierungsanmeldung am 7. Januar 2025 für wirksam, wobei eine nachträgliche Änderung am 27. Januar 2025 genehmigt wurde.
- Successful IPO raising $200 million in gross proceeds
- Listed on Nasdaq Global Market
- Unit structure provides additional value potential through 1/8 share rights
- Proceeds subject to reduction from underwriting discounts and offering expenses
Insights
The successful completion of Drugs Made In America Acquisition Corp's
Key Strategic Elements:
- The unit structure, combining one share with a one-eighth right, provides investors with additional upside potential while maintaining a balanced risk profile compared to traditional warrant-based SPAC units
- The domestic pharmaceutical manufacturing focus aligns with current regulatory and political priorities around reshoring critical supply chains
- Clear Street's sole book-running role suggests a focused distribution strategy, potentially leading to a more concentrated and strategic investor base
Market Positioning:
- The timing coincides with renewed interest in pharmaceutical manufacturing investments, driven by supply chain resilience initiatives and regulatory support
- The
$200 million size positions the SPAC to target mid-market pharmaceutical manufacturing assets, a segment with numerous potential acquisition targets - The Nasdaq listing provides essential liquidity and visibility for institutional investors
The successful pricing at
Fort Lauderdale, FL, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU), (the “Company”) today announced that it closed its initial public offering of 20,000,000 units at
Each unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the ordinary shares and rights are expected to be listed on Nasdaq under the symbols "DMAA" and "DMAAR", respectively.
Clear Street acted as the sole book-running manager in the offering. Loeb & Loeb LLP served as legal counsel to the Company. Winston & Strawn LLP served as legal counsel to Clear Street.
The offering was made only by means of a prospectus, copies of which may be obtained from Clear Street, Attn: Syndicate Department, 150 Greenwich Street, 45th floor, New York, NY 10007, or by email at ecm@clearstreet.io. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission ("SEC") on January 7, 2025 and a post-effective amendment was declared effective by the SEC on January 27, 2025.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Drugs Made In America Acquisition Corp.
The Company is a blank check company incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It has not selected any specific business combination target and has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination. While the Company may pursue a business combination target in any business, industry or geographical location, it intends to focus its search for businesses in the pharmaceutical industry. The Company believes that it is possible to mitigate risks in the U.S. medical supply chain by investing in companies that will reduce America’s overreliance on production of pharmaceuticals from concentrated geographic regions through investments in strategic on-shoring of advanced domestic manufacturing technologies for critical drugs.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement, as amended by the post-effective amendment, and related preliminary prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact Information
Drugs Made In America Acquisition Corp.
1 East Broward Boulevard, Suite 700
Fort Lauderdale, FL 33301
Lynn Stockwell
Chief Executive Officer and Executive Chair
Email: executive@dmaacorp.com
Phone: (954) 870-3099
FAQ
How much did Drugs Made In America Acquisition Corp. (DMAAU) raise in its IPO?
What is included in each DMAAU IPO unit?
When did DMAAU begin trading on Nasdaq?
What will be the separate trading symbols for DMAAU's ordinary shares and rights?
When was DMAAU's registration statement declared effective by the SEC?
